SGMO_OUT_1 [2025-04-03 16:48:30 -0400] 2879 Bytes | 756 tokens | Cum: 756 tkns (9.45% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 4:48:30 PM on Thu Apr 03, 2025 -0400, and I'm firing up the spotlight on Sangamo Therapeutics (SGMO), moving from 0.6532 to 0.7993. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Sangamo Therapeutics (SGMO)
IPO: 2000-04-06 (25 Years Ago)
Market Cap: $133,477,751
Shares Outstanding: 224,710,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Here's the first list of news for Sangamo Therapeutics:

C1 - Today 04:01PM - Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
C2 - Mar-18-25 09:00AM - Q4 2024 Sangamo Therapeutics Inc Earnings Call
C3 - Mar-18-25 09:00AM 03:01AM - Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
C4 - Mar-17-25 05:10PM - Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
C5 - Mar-17-25 05:10PM 04:20PM - Sangamo: Q4 Earnings Snapshot
C6 - Mar-17-25 05:10PM 04:01PM - Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
C7 - Mar-06-25 04:05PM - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
C8 - Feb-06-25 08:05AM - Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Sangamo Therapeutics (SGMO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SGMO_OUT_3 [2025-04-03 16:48:35 -0400] 573 Bytes | 165 tokens | Cum: 923 tkns (11.54% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System**
Date: Today 04:01PM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250403023818/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250403023818/en/

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_5 [2025-04-03 16:48:36 -0400] 977 Bytes | 287 tokens | Cum: 1300 tkns (16.25% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T20:06:00Z - Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Capsid License Agreement With Lilly to De...
A2 - 2025-03-19T15:44:11Z - Sangamo Therapeutics (NASDAQ:SGMO) Receives Sector Perform Rating from Royal Bank of Canada...
A3 - 2025-03-18T20:00:59Z - 8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Sangamo Therapeutics (NASDAQ:SGMO)...
A4 - 2025-03-18T21:14:54Z - Sangamo Therapeutics (NASDAQ:SGMO) Announces Earnings Results, Misses Estimates By $0.02 EPS...
A5 - 2025-03-18T20:53:02Z - Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SGMO_OUT_7 [2025-04-03 16:48:39 -0400] 1098 Bytes | 301 tokens | Cum: 1603 tkns (20.04% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System**Date: 2025-04-03Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-04/65023876-sangamo-therapeutics-inc-sangamo-therapeutics-announces-capsid-license-agreement-with-lilly-to-deliver-genomic-medicines-for-diseases-of-the-centra-004.htmAgreement grants Lilly rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales

Sangamo Therapeutic

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_9 [2025-04-03 16:48:40 -0400] 1194 Bytes | 365 tokens | Cum: 2083 tkns (26.04% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-18T10:16:53Z - US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
B2 - 2025-02-21T18:00:00Z - Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
B3 - 2025-01-02T07:30:00Z - Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI
B4 - 2024-12-31T14:14:19Z - Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
B5 - 2024-12-08T13:00:00Z - mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider
B6 - 2024-11-22T07:27:00Z - Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SGMO_OUT_11 [2025-04-03 16:48:43 -0400] 906 Bytes | 276 tokens | Cum: 2361 tkns (29.51% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/02/3003317/0/en/Global-Mucopolysaccharidosis-Treatment-Market-to-Witness-Robust-Growth-Projected-to-Reach-USD-5-014-5-Million-by-2035-Growing-at-a-CAGR-of-5-9-FMI.htmlThe global mucopolysaccharidosis treatment market is expected to grow significantly, driven by advancements in biotechnology, improved diagnostic techniques, and increased awareness of rare diseases. The market is projected to reach $5,014.5 million by 2035, growing at a CAGR of 5.9%.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_13 [2025-04-03 16:48:44 -0400] 770 Bytes | 203 tokens | Cum: 2638 tkns (32.98% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-17 10-K ITEM 7 MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The discussion in Mgts Discussion and Analysis of Fin Cond and Results of Oper contains trend analysis, estimates and other forward-looking statements within the...

S2 - 2025-03-17 8-K Item 2.02 Results of Oper and Fin Cond.

On March 17, 2025, Sangamo Therapeutics, Inc. (Sangamo) issued a press release announcing its financial results for the year ended December 31, 2024 (the Press Release).

A copy of the Press Release is furnished hereto a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SGMO_OUT_15 [2025-04-03 16:48:45 -0400] 1098 Bytes | 239 tokens | Cum: 2879 tkns (35.99% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The discussion in Managements Discussion and Analysis of Financial Condition and Results of Operations contains trend analysis, estimates and other forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, without limitation, statements containing the words anticipates, believes, continues, could, estimates, expects, intends, may, plans, seeks, should, will, and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, perf

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_17 [2025-04-03 16:48:56 -0400] 6213 Bytes | 1951 tokens | Cum: 4832 tkns (60.40% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-------------------------+
| Volume: 14,617,566 | Perf Month: -28.87% | Option/Short: Yes / Yes | Sales Y/Y TTM: -67.20% |
+--------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 5.37M | Perf Quarter: -38.99% | Short Float: 13.47% | ROE: -187.83% |
+--------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 2.72 | Index: - | Short Ratio: 5.38 | ROI: -202.41% |
+--------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 32.00 | Market Cap: 139.84M | Short Interest: 28.91M | Sales Surprise: -35.46% |
+--------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.10 | Shs Outstand: 224.71M | Beta: 1.50 | EPS Surprise: -20.48% |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -27.16% | Shs Float: 214.59M | Sales Q/Q: 269.78% | P/E: - |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -37.96% | Inst Own: 27.61% | Sales past 5Y: 0.15% | Earnings: Mar 17 AMC |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -46.60% | Insider Own: 4.50% | Employees: 183 | |
+--------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -27.41% | Insider Trans: 0.00% | Debt/Eq: 1.34 | |
+--------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Davis Gregory D (Head of Research & Technology) on 2025-02-24
- Common Stock: 705 shares at $1 (D)
- Common Stock: 507 shares at $0.9561 (D)
- Common Stock: 49726 shares at $0 (D)
- Stock Option (Right to Buy): 99454 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Dubois-Stringfellow Nathalie (SVP-CHIEF DEVELOPMENT OFFICER) on 2025-02-24
- Common Stock: 1792 shares at $1 (D)
- Common Stock: 1513 shares at $0.9561 (D)
- Common Stock: 120000 shares at $0 (D)
- Stock Option (Right to Buy): 560000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Willoughby Scott B. (SVP, GEN. COUNSEL & SECRETARY) on 2025-02-24
- Common Stock: 1434 shares at $1 (D)
- Common Stock: 1375 shares at $0.9561 (D)
- Common Stock: 120000 shares at $0 (D)
- Stock Option (Right to Buy): 560000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Duraibabu Prathyusha (SVP, CHIEF FINANCIAL OFFICER) on 2025-02-24
- Common Stock: 1792 shares at $1 (D)
- Common Stock: 1375 shares at $0.9561 (D)
- Common Stock: 120000 shares at $0 (D)
- Stock Option (Right to Buy): 560000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Macrae Sandy (PRESIDENT, CEO AND DIRECTOR) on 2025-02-24
- Common Stock: 7488 shares at $1 (D)
- Common Stock: 10663 shares at $0.9561 (D)
- Common Stock: 375000 shares at $0 (D)
- Stock Option (Right to Buy): 1750000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Willoughby Scott B. (SVP, GEN. COUNSEL & SECRETARY) on 2025-01-22
- Common Stock: 129549 shares at $1.15 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Duraibabu Prathyusha (SVP, CHIEF FINANCIAL OFFICER) on 2025-01-22
- Common Stock: 129242 shares at $1.15 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Dubois-Stringfellow Nathalie (SVP-CHIEF DEVELOPMENT OFFICER) on 2025-01-22
- Common Stock: 129593 shares at $1.15 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 57800000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -97941000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.6223
Average Volume: 7108117.09
30-Day High: 1.04
30-Day Low: 0.5701

[Detailed Financials: TTM 2024]
- Total Assets: $101,635,000.0
- Total Liabilities: $78,865,000.0
- Total Equity: $22,770,000.0
- Current Assets: $51,691,000.0
- Current Liabilities: $45,805,000.0

[Income Statement: TTM 2024]
- Revenue: $57,800,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.49

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-3,286,000.0

[Detailed Financials: FY 2024]
- Total Assets: $101,635,000.0
- Total Liabilities: $78,865,000.0
- Total Equity: $22,770,000.0
- Current Assets: $51,691,000.0
- Current Liabilities: $45,805,000.0

[Income Statement: FY 2024]
- Revenue: $57,800,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.49

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-3,286,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SGMO_OUT_19 [2025-04-03 16:48:58 -0400] 676 Bytes | 167 tokens | Cum: 5292 tkns (66.15% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SGMO_IN_21 [2025-04-03 16:48:58 -0400] 126 Bytes | 29 tokens | Cum: 5348 tkns (66.85% of 8k)
==========================================================================

====================================
[2025-04-03 16:48:58] # Analysis Completed
Elapsed Time: 28.33 seconds